New Mexico Legalizes Medical Psilocybin: A Bold Step Toward Healing and Mental Health Reform

On April 7, 2025, New Mexico Governor Michelle Lujan Grisham signed into law the Medical Psilocybin Act (Senate Bill 219), making New Mexico the third state in the U.S. to legalize medical psilocybin therapy, following Oregon and Colorado.

A New Frontier in Mental Health Treatment

The Medical Psilocybin Act establishes a regulated program allowing patients with specific qualifying conditions to access psilocybin-assisted therapy under the supervision of licensed healthcare providers. Qualifying conditions include:

• Major treatment-resistant depression
• Post-traumatic stress disorder (PTSD)
• Substance use disorders
• End-of-life care
• Other conditions approved by the New Mexico Department of Health

Therapy will consist of three phases: a preparation session, an administration session, and a follow-up integration session. Only naturally occurring psilocybin is permitted; synthetic versions are excluded from the program.

Oversight and Implementation

The New Mexico Department of Health is tasked with developing and overseeing the program, which must be fully implemented by December 31, 2027. A nine-member Medical Psilocybin Advisory Board will assist in establishing best practices, dosage standards, and qualifying conditions. The board will include representatives from tribal communities, mental health equity advocates, healthcare authorities, and U.S. military veterans.

Equity and Research Initiatives

To promote accessibility and scientific understanding, the Act creates two funds:

• Medical Psilocybin Treatment Equity Fund: Provides financial assistance for low-income patients seeking psilocybin therapy.
• Medical Psilocybin Research Fund: Offers grants to state research universities and healthcare providers studying various aspects of medical psilocybin use.

Legal Protections and Restrictions

Participants in the program—including patients, clinicians, and producers—are protected from criminal and civil penalties when operating within the law. However, unauthorized use, including driving under the influence of psilocybin, remains prohibited.

Looking Ahead

New Mexico’s legislative approach to legalizing medical psilocybin sets a precedent for other states considering similar measures. As the program develops, it aims to provide new avenues for treating mental health conditions and contribute to the broader understanding of psilocybin’s therapeutic potential.

For more information on the Medical Psilocybin Act and its implementation, visit the New Mexico Legislature’s official page for SB 219.